Clinical experience of cerebrospinal fluid-based liquid biopsy demonstrates superiority of cell-free DNA over cell pellet genomic DNA for molecular profiling Journal Article
| Authors: | Bale, T. A.; Yang, S. R.; Solomon, J. P.; Nafa, K.; Middha, S.; Casanova, J.; Sadowska, J.; Skakodub, A.; Ahmad, H.; Yu, H. A.; Riely, G. J.; Kris, M. G.; Chandarlapaty, S.; Rosenblum, M. K.; Gavrilovic, I.; Karajannis, M. A.; Pentsova, E.; Miller, A.; Boire, A.; Mellinghoff, I.; Berger, M. F.; Zehir, A.; Ladanyi, M.; Benayed, R.; Arcila, M. E. |
| Article Title: | Clinical experience of cerebrospinal fluid-based liquid biopsy demonstrates superiority of cell-free DNA over cell pellet genomic DNA for molecular profiling |
| Abstract: | Cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) offers unique opportunities for genomic profiling of tumors involving the central nervous system but remains uncommonly used in clinical practice. We describe our clinical experience using cfDNA from CSF for routine molecular testing using Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (targeting 468 cancer-related genes). In all, 148 cfDNA samples were assessed, comparing results of cfDNA versus genomic DNA (gDNA; gDNA from cell pellets) derived from the same CSF sample and the primary tumor. Of these, 71.6% (106/148) were successfully sequenced. Somatic alterations (mutations and fusions) were observed in 70.8% (75/106) of the samples; 97.3% (73/75) comprised variants confirming central nervous system involvement by a previously diagnosed tumor, 14.7% (11/75) had additional variants consistent with a therapy-related resistance mechanism, and 2.7% (2/75) had variants that independently diagnosed a new primary. Among samples with paired cfDNA and gDNA sequencing results, cfDNA was more frequently positive for at least one mutation [43.6% (55/126) versus 19.8% (25/126)] and harbored 1.6× more mutations (6.94 versus 4.65; P = 0.005), with higher mean variant allele fractions (41.1% versus 13.0%; P < 0.0001). Among mutation-positive cfDNAs, the corresponding gDNA was frequently negative (44.6%; 25/55) or failed sequencing (17.8%; 9/55). Routine molecular profiling of cfDNA is superior to gDNA from CSF, facilitating the capture of mutations at high variant allele frequency, even in the context of a negative cytology. © 2021 Association for Molecular Pathology and American Society for Investigative Pathology |
| Journal Title: | Journal of Molecular Diagnostics |
| Volume: | 23 |
| Issue: | 6 |
| ISSN: | 1525-1578 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2021-06-01 |
| Start Page: | 742 |
| End Page: | 752 |
| Language: | English |
| DOI: | 10.1016/j.jmoldx.2021.03.001 |
| PUBMED: | 33781965 |
| PROVIDER: | scopus |
| PMCID: | PMC8207471 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work